Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2021

Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2021

  • July 2021 •
  • 60 pages •
  • Report ID: 6124403 •
  • Format: PDF
“Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Intrahepatic Cholangiocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Intrahepatic Cholangiocarcinoma Understanding

Intrahepatic Cholangiocarcinoma: Overview
Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

"Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines. The assessment part of the report embraces, in depth Intrahepatic Cholangiocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intrahepatic Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Intrahepatic Cholangiocarcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Intrahepatic Cholangiocarcinoma.

Intrahepatic Cholangiocarcinoma Emerging Drugs Chapters
This segment of the Intrahepatic Cholangiocarcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Intrahepatic Cholangiocarcinoma Emerging Drugs
• Derazantinib: Basilea Pharmaceutica
Derazantinib is an orally administered small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family of kinases. Derazantinib is currently in a registrational phase 2 study inIntrahepatic cholangiocarcinoma (iCCA). In January 2019, Basilea reported results from an interim analysis from this study. The efficacy results were encouraging and the analysis also confirmed the safety profile and tolerability of derazantinib observed in previous clinical studies.

• Durvalumab: AstraZeneca
Durvalumab is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Further product details are provided in the report……..

Intrahepatic Cholangiocarcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Intrahepatic Cholangiocarcinoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Intrahepatic Cholangiocarcinoma
There are approx. 20+ key companies which are developing the therapies for Intrahepatic Cholangiocarcinoma. The companies which have their Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage, i.e. phase II include, Basilea Pharmaceutica.

• Phases
This report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Intrahepatic Cholangiocarcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Intrahepatic Cholangiocarcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Intrahepatic Cholangiocarcinoma drugs.

Intrahepatic Cholangiocarcinoma Report Insights
• Intrahepatic Cholangiocarcinoma Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Intrahepatic Cholangiocarcinoma Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Intrahepatic Cholangiocarcinoma drugs?
• How many Intrahepatic Cholangiocarcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Intrahepatic Cholangiocarcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Intrahepatic Cholangiocarcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Intrahepatic Cholangiocarcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Basilea Pharmaceutica
• AstraZeneca
• Delcath Systems Inc.
• Jiangsu HengRui Medicine Co., Ltd.
• Syndax Pharmaceuticals
• Hutchison Medipharma Limited
• Medivir
• Newish Technology (Beijing) Co., Ltd.
• Relay Therapeutics, Inc.
• Exelixis
• Forma Therapeutics, Inc.
• Xencor, Inc.
• Zymeworks
• RedHill Biopharma Limited
• Genoscience Pharma
• Kinnate Biopharma
• Taiho Oncology, Inc.
• Sirtex Medical

Key Products
• Derazantinib
• Durvalumab
• Melphalan/HDS
• Apatinib
• SNDX-6352
• Camrelizumab
• Tremelimumab
• HMPL-453
• MIV-818
• Autologous Tcm cellular immunotherapy
• RLY-4008
• Cabozantinib
• FT-2102
• XmAb®22841
• ZW25
• ABC294640
• GNS561
• TAS-120